Clinical Trial Results:
A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (CGX-635) in the Treatment of Patients with Chronic Myeloid Leukemia (CML) who have failed or are intolerant to tyrosine kinase inhibitor therapy
Summary
|
|
EudraCT number |
2007-001286-15 |
Trial protocol |
HU FR GB DE IT |
Global completion date |
27 Jun 2013
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
28 Dec 2016
|
First version publication date |
28 Dec 2016
|
Other versions |
|
Summary report(s) |
CGX-635-CML-203~ |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.